Protective Effect of Niclosamide on Lipopolysaccharide-induced Sepsis in Mice by Modulating STAT3 Pathway
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Sepsis is a systemic inflammatory response, with manifestations in multiple organs by pathogenic infection. Currently, there are no promising therapeutic strategies. Signal transducer and activator of transcription 3 (STAT3) is a cell signaling transcription factor. Niclosamide is an anti-helminthic drug approved by the Food and Drug Administration (FDA) as a potential STAT3 inhibitor. C57BL/6 mice were treated with an intraperitoneal injection of lipopolysaccharide (LPS). Niclosamide was administered orally 2 hours after the LPS injection. This study found that Niclosamide improved the survival and lung injury of LPS-induced mice. Niclosamide decreased the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) in serum. The effects of Niclosamide on phosphoinositide 3-kinase (PI3K), AKT, nuclear factor-κB (NF-κB), and STAT3 signaling pathways were determined in the lung tissue by immunoblot analysis. Niclosamide reduced phosphorylation of PI3K, AKT, NF-κB, and STAT3 significantly. Furthermore, it reduced the phosphorylation of STAT3 by LPS stimulation in RAW 264.7 macrophages. Niclosamide also reduced the LPS-stimulated expression of proinflammatory mediators, including IL-6, TNF-α, and IL-1β. Niclosamide provides a new therapeutic strategy for murine sepsis models by suppressing the inflammatory response through STAT3 inhibition.
Abstract
Sepsis is a systemic inflammatory response, with manifestations in multiple organs by pathogenic infection. Currently, there are no promising therapeutic strategies. Signal transducer and activator of transcription 3 (STAT3) is a cell signaling transcription factor. Niclosamide is an anti-helminthic drug approved by the Food and Drug Administration (FDA) as a potential STAT3 inhibitor. C57BL/6 mice were treated with an intraperitoneal injection of lipopolysaccharide (LPS). Niclosamide was administered orally 2 hours after the LPS injection. This study found that Niclosamide improved the survival and lung injury of LPS-induced mice. Niclosamide decreased the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) in serum. The effects of Niclosamide on phosphoinositide 3-kinase (PI3K), AKT, nuclear factor-κB (NF-κB), and STAT3 signaling pathways were determined in the lung tissue by immunoblot analysis. Niclosamide reduced phosphorylation of PI3K, AKT, NF-κB, and STAT3 significantly. Furthermore, it reduced the phosphorylation of STAT3 by LPS stimulation in RAW 264.7 macrophages. Niclosamide also reduced the LPS-stimulated expression of proinflammatory mediators, including IL-6, TNF-α, and IL-1β. Niclosamide provides a new therapeutic strategy for murine sepsis models by suppressing the inflammatory response through STAT3 inhibition.
참고문헌 (27)
- Cecconi M, "Sepsis and septic shock", Lancet, 392, pp.75~87 (2018)[DOI]
- Schulte W, "Cytokines in sepsis : potent immunoregulators and potential therapeutic targets--an updated view", Mediators Inflamm, 2013, pp.165974~ (2013)[DOI]
- Beutler B, "Innate immune sensing and its roots : the story of endotoxin", Nat Rev Immunol, 3, pp.169~176 (2003)[DOI]
- Remick DG, "Comparison of the mortality and inflammatory response of two models of sepsis:lipopolysaccharide vs. cecal ligation and puncture", Shock, 13, pp.110~116 (2000)[DOI]
- Monsalve E, "Notch1 upregulates LPS-induced macrophage activation by increasing NF-kappaB activity", Eur J Immunol, 39, pp.2556~2570 (2009)[DOI]
- Fink MP, "Strategies to improve drug development for sepsis", Nat Rev Drug Discov, 13, pp.741~758 (2014)[DOI]
- Ranieri VM, "Drotrecogin alfa (activated) in adults with septic shock", N Engl J Med, 366, pp.2055~2064 (2012)[DOI]
- Chen W, "Niclosamide: beyond an antihelminthic drug", Cell Signal, 41, pp.89~96 (2018)[DOI]
- Sack U, "Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer", J Natl Cancer Inst, 103, pp.1018~1036 (2011)[DOI]
- Yo YT, "Growth inhibition of ovarian tumor-initiating cells by niclosa-mide", Mol Cancer Ther, 11, pp.1703~1712 (2012)[DOI]
- Ren X, "Identification of niclosamide as a new small-molecule inhibitor of the STAT3signaling pathway", ACS Med Chem Lett, 1, pp.454~459 (2010)[DOI]
- Hillmer EJ, "STAT3 signaling in immunity", Cytokine Growth Factor Rev, 31, pp.1~15 (2016)[DOI]
- Akira S, "Molecular cloning of APRF, a novel IFN-stimulated gene factor 3p91-related transcription factor involved in the gp130-mediated signaling pathway", Cell, 77, pp.63~71 (1994)[DOI]
- Hilliard KL, "Activation of hepatic STAT3 maintains pulmonary defense during endotoxemia", Infect Immun, 83, pp.4015~4027 (2015)[DOI]
- Huang W, "Long non-coding RNA DILC is involved in sepsis by modulating the signaling pathway of the interleukin-6", signal transducer and activator of transcription 3, Mol Med Rep, pp.2018, 18[DOI]
- Fang X, "Human mesenchymal stem(stromal)cells promote the resolution of acute lung injury in part through lipoxin A4", J Immunol, 195, pp.875~881 (2015)[DOI]
- Cao Z, "AKT and ERK dual inhibitors : the way forward?", Cancer Lett, 459, pp.30~40 (2019)[DOI]
- Fleischmann-Struzek C, "Challenges in assessing the burden of sepsis and understanding the inequalities of sepsis outcomes between National Health Systems : secular trends in sepsis and infection incidence and mortality in Germany", Intensive Care Med, 44, pp.1826~1835 (2018)
- Su BC, "Epinecidin-1 protects mice from LPS-induced endotoxemia and cecal ligation and puncture-induced polymicrobial sepsis", Biochim Biophys Acta Mol Basis Dis, 1863, pp.3028~3037 (2017)[DOI]
- Zilberberg MD, "Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock : a retrospective cohort study", Crit Care, 18, pp.596~ (2014)[DOI]
- Moriyama K, "Targeting cytokines, pathogen-associated molecular patterns, and damage-associated molecular patterns in sepsis via blood purification", Int J Mol Sci, 22, pp.8882~ (2021)[DOI]
- Kubes P, "Immune responses in the liver", Annu Rev Immunol, 36, pp.247~277 (2018)[DOI]
- Beyer D, "The liver in sepsis : molecular mechanism of liver failure and their potential for clinical translation", Mol Med, 28, pp.84~ (2022)[DOI]
- Meng A, "Role of p38 MAPK and STAT3 in lipopolysaccharide-stimulated mouse alveolar macrophages", Exp Ther Med, 8, pp.1772~1776 (2014)[DOI]
- Xia T, "Advances in the role of STAT3 in macrophage polarization", Front Immunol, 14, pp.1160719~ (2023)[DOI]
- Vergadi E, "Akt signaling pathway in macrophage activation and M1", M2 polarization, 2017, pp.198, 1006~1014
- Matsukawa A, "Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils", J Immunol, 171, pp.6198~6205 (2003)[DOI]